Summary
Age-related macular degeneration (AMD) is the most common cause of irreversible blindness and visual impairment in individuals over the age of 50 years in western societies. More than 25 million people currently suffer from this illness in the world, with an additional 500 000 every year, approximately. It is a multifactorial ocular disease that affects the maculae due to a late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). There are many subtypes of AMD but basically two broad forms: the nonneovascular (dry, nonexudative) and neovascular (wet, exudative). Exudative AMD is the less common form (about 15%) but tends to progress more rapidly. At the moment, wet AMD is treated primarily on the basis of anti-vascular endothelial growth factor (VEGF) agents, which have led to massive improvement in the prognosis of the disease since they were first introduced. This article focuses on the latest treatment approaches to neovascular AMD. An extensive literature review was performed in order to illustrate the effectiveness of current and future anti-VEGF agents as well as the landmark clinical studies that have been carried out to establish these drugs as a gold standard in the therapy of wet AMD.
Similar content being viewed by others
References
Yonekawa Y, Kim IK. Clinical characteristics and current treatment of age-related macular degeneration. Cold Spring Harb Perspect Med, 2015,5(1):a017178
Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica, 2012,227 (Suppl. 1):11–20
Yanoff M, Duker JS. Age-Related Macular Degeneration. Ophthalmology 4th edition. Elsevier Saunders. 2014:580–604.
Kanski JJ, Bowling B. Acquired Macular Disorders. Clinical ophthalmology: a systematic approach 7th edition. Elsevier Health Sciences. 2011:594–646.
Denniston A, Murray P, editors. Medical Retina. Oxford handbook of ophthalmology. OUP Oxford. 2014:515–592.
Gerhard K. Lang. Retina. Ophthalmology: A Pocket Textbook Atlas. Thieme. 2007:305–372.
Kanski JJ, Bowling B. Acquired Macular Disorders. Synopsis of Clinical Ophthalmology 3rd edition. Elsevier Health Sciences. 2013:268–287.
García-Layana A, Figueroa MS, Araiz J, et al. Treatment of exudative age-related macular degeneration: focus on aflibercept. Drugs Aging, 2015,32(10):797–807
Kanski JJ, Bowling B. Acquired Macular Disorders. Clinical ophthalmology: a systematic approach 8th edition. Elsevier Health Sciences. 2016:580–639.
Coscas G. Optical coherence tomography in age-related macular degeneration. Springer Science & Business Media. 2009 Jul 25.
Ma J, Desai R, Nesper P, et al.. Optical Coherence Tomographic Angiography Imaging in Age-Related Macular Degeneration. Ophthalmol Eye Dis, 2017,9:1179172116686075
Ly A, Nivison-Smith L, Assaad N, et al. Fundus autofluorescence in age-related macular degeneration. Optometry Vis Sci, 2017,94(2):246
Peng Q, Dong Y, Zhao PQ. Fundus autofluorescence in exudative age-related macular degeneration. Genet Mol Res, 2013,12(4):6140–6148
Shao J, Choudhary MM, Schachat AP.. Neovascular age-related macular degeneration. Dev Ophthalmol, 2016,55:125–136
Al-Zamil WM, Yassin SA.. Recent developments in age-related macular degeneration: a review. Clin Interv Aging, 2017,12:1313
Petrarca R, Jackson TL. Radiation therapy for neovascular age-related macular degeneration. Clin Ophthalmol (Auckland, NZ). 2011,5:57
Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study. Ophthalmology, 2013,120(9):1893–1900
Neffendorf JE, Jackson TL.. Stereotactic radiotherapy for wet age-related macular degeneration: current perspectives. Clin Ophthalmol (Auckland, NZ), 2015,9:1829
Pożarowska D, Pożarowski P. The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol, 2016,41(3):311
Hassan M, Afridi R, Sadiq MA, et al. The role of Aflibercept in the management of age-related macular degeneration. Expert Opin Biol Ther, 2016,16(5):699–709
Ba J, Peng RS, Xu D, et al.. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des Dev Ther, 2015,9:5397–9405
Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother, 2012,13(4):585–591
Balaratnasingam C, Dhrami-Gavazi E, McCann JT, et al.. Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clin Ophthalmol (Auckland, NZ), 2015,9:2355
Papadopoulos Z. Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration. Eur J Ophthalmol, 2019,29(4):368–378
Frampton JE. Aflibercept for intravitreal injection. Drugs Aging, 2012,29(10):839–846
Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye, 2013,27(7):787–794
Costagliola C, Agnifili L, Arcidiacono B, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther, 2012,12(10):1299–1313
Rayess N, Houston III SS, Gupta OP, et al. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol, 2015,159(1):3–8
Chin-Yee D, Eck T, Fowler S, et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol, 2016,100(7):914–917
Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology, 2015,122(12):2514–2522
Wykoff CC, Ou WC, Brown DM, et al. Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study. Ophthalmol Retina, 2017,1(4):314–321
Augsburger M, Sarra GM, Imesch P. Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol Graefes Arch Clin Exp Ophthalmol, 2019,257(9):1889–1895
Holekamp NM. Review of neovascular age-related macular degeneration treatment options. Am J Managed Care, 2019,25(10 Suppl):S172–181
Sharma A, Kumar N, Kuppermann BD, et al.. Abicipar pegol: the non-monoclonal antibody anti-VEGF. Eye, 2019,30:1–5
Lu X, Sun X.. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des, Dev Ther, 2015,9:2311–2320
Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology, 2014,121(9):1740–1747
Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology, 2019,127(1):72–84
Markham A. Brolucizumab: First Approval. Drugs, 2019,79(18):1997–2000
Boxler D. Brolucizumab-dbll Approved by FDA for Wet AMD.
Yannuzzi NA, Freund KB. Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol (Auckland, NZ) 2019,13:1323–1329
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflict of Interest Statement
There is no conflict of interest.
Rights and permissions
About this article
Cite this article
Papadopoulos, Z. Recent Developments in the Treatment of Wet Age-related Macular Degeneration. CURR MED SCI 40, 851–857 (2020). https://doi.org/10.1007/s11596-020-2253-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-020-2253-6